Panbela Therapeutics, Inc. – NASDAQ:PBLA
Panbela Therapeutics stock price today
$0.158
-0.17
-52.15%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 1 day
Panbela Therapeutics stock price monthly change
-6.22%
month
Panbela Therapeutics stock price quarterly change
-6.22%
quarter
Panbela Therapeutics stock price yearly change
-63.78%
year
Panbela Therapeutics key metrics
Market Cap | 1.57M |
Enterprise value | 75.62K |
P/E | -0.01 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | -0.04 |
PEG ratio | N/A |
EPS | -215.13 |
Revenue | N/A |
EBITDA | -35.21M |
Income | -27.25M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freePanbela Therapeutics stock price history
Panbela Therapeutics stock forecast
Panbela Therapeutics financial statements
| Jun 2023 | 0 | -5.83M | |
|---|---|---|---|
| Sep 2023 | 0 | -7.83M | |
| Dec 2023 | 0 | -6.47M | |
| Mar 2024 | 0 | -7.12M |
| 2027 | 61.66M | -712 | 0% |
|---|
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 19551000 | 14.74M | 75.44% |
|---|---|---|---|
| Sep 2023 | 10628000 | 13.11M | 123.36% |
| Dec 2023 | 11802000 | 16.51M | 139.91% |
| Mar 2024 | 10527000 | 13.71M | 130.27% |
| Jun 2023 | -5.74M | 7.96M | 7.70M |
|---|---|---|---|
| Sep 2023 | -6.67M | 400K | -19K |
| Dec 2023 | -3.08M | -7.96M | 4.74M |
| Mar 2024 | -9.39M | 0 | 7.08M |
Panbela Therapeutics alternative data
| Aug 2023 | 6 |
|---|---|
| Sep 2023 | 6 |
| Oct 2023 | 6 |
| Nov 2023 | 6 |
| Dec 2023 | 6 |
| Jan 2024 | 6 |
| Feb 2024 | 6 |
| Mar 2024 | 6 |
| Apr 2024 | 6 |
| May 2024 | 7 |
| Jun 2024 | 7 |
| Jul 2024 | 7 |
Panbela Therapeutics other data
100.00%
+66.87%
of PBLA is owned by hedge funds
121.69K
+109.68K
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Nov 2024 | 0 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | NANT CAPITAL, LLC 10 percent owner | 8% Senior Convertible Note due 2025 | 0 | $0.37 | $0 | ||
Sale | GOLDMAN SACHS GROUP INC 10 percent owner | Common Stock | 72,874 | $0.71 | $51,741 | ||
Purchase | HORVATH SUSAN officer: V.P. of .. | Warrants (right to buy) | 8,888 | $2.75 | $24,442 | ||
Purchase | HORVATH SUSAN officer: V.P. of .. | Common Stock | 4,444 | N/A | N/A | ||
Purchase | SIMPSON JENNIFER K. director, officer: President an.. | Warrants (right to buy) | 8,888 | $2.75 | $24,442 | ||
Purchase | SIMPSON JENNIFER K. director, officer: President an.. | Common Stock | 4,444 | N/A | N/A | ||
Purchase | JACOB JEFFREY E. director | Common Stock | 33,000 | N/A | N/A | ||
Purchase | SCHEMEL DONALD ROBERT director, 10 percent owner | Warrants (right to buy) | 300,000 | $0.3 | $90,000 | ||
Purchase | SCHEMEL DONALD ROBERT director, 10 percent owner | Common Stock | 200,000 | N/A | N/A | ||
Purchase | CULLEN MICHAEL T. director, 10 percent owner | Common Stock | 165,000 | N/A | N/A |
| Quarter | Transcript |
|---|---|
| Q1 2024 15 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 26 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 10 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 10 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Dr. Jennifer K. Simpson C.R.N.P., CRNP, M.S.N., Ph.D. (1968) Chief Executive Officer, Pres & Director | $369,920 |
| Ms. Susan Horvath (1959) Vice President of Fin., Chief Financial Officer, Sec. & Treasurer | $316,000 |
-
What's the price of Panbela Therapeutics stock today?
One share of Panbela Therapeutics stock can currently be purchased for approximately $0.16.
-
When is Panbela Therapeutics's next earnings date?
Unfortunately, Panbela Therapeutics's (PBLA) next earnings date is currently unknown.
-
Does Panbela Therapeutics pay dividends?
No, Panbela Therapeutics does not pay dividends.
-
How much money does Panbela Therapeutics make?
Panbela Therapeutics has a market capitalization of 1.57M.
-
What is Panbela Therapeutics's stock symbol?
Panbela Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "PBLA".
-
What is Panbela Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Panbela Therapeutics?
Shares of Panbela Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Panbela Therapeutics's key executives?
Panbela Therapeutics's management team includes the following people:
- Dr. Jennifer K. Simpson C.R.N.P., CRNP, M.S.N., Ph.D. Chief Executive Officer, Pres & Director(age: 57, pay: $369,920)
- Ms. Susan Horvath Vice President of Fin., Chief Financial Officer, Sec. & Treasurer(age: 66, pay: $316,000)
-
How many employees does Panbela Therapeutics have?
As Jul 2024, Panbela Therapeutics employs 7 workers, which is 17% more then previous quarter.
-
When Panbela Therapeutics went public?
Panbela Therapeutics, Inc. is publicly traded company for more then 8 years since IPO on 3 Jan 2017.
-
What is Panbela Therapeutics's official website?
The official website for Panbela Therapeutics is panbela.com.
-
Where are Panbela Therapeutics's headquarters?
Panbela Therapeutics is headquartered at 712 Vista Boulevard, Waconia, MN.
-
How can i contact Panbela Therapeutics?
Panbela Therapeutics's mailing address is 712 Vista Boulevard, Waconia, MN and company can be reached via phone at +95 2 479 1196.
Panbela Therapeutics company profile:
Panbela Therapeutics, Inc.
panbela.comExchange:
NASDAQ
Full time employees:
7
Industry:
Biotechnology
Sector:
Healthcare
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer, as well as neoadjuvant pancreatic cancer, colorectal cancer, ovarian cancer, and other agents in other cancer indications. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.
712 Vista Boulevard
Waconia, MN 55387
Waconia, MN 55387
CIK: 0001029125
ISIN: US69833W4042
CUSIP: 69833W107
